Research programme: combined Hendra and Nipah virus vaccine - Profectus BioSciences

Drug Profile

Research programme: combined Hendra and Nipah virus vaccine - Profectus BioSciences

Alternative Names: HeV vaccine; HeV-sG; NiV vaccine

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Profectus Biosciences
  • Developer CSIRO; Profectus Biosciences
  • Class Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Viral infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in USA
  • 10 May 2012 Preclinical trials in Viral infections in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top